<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132849">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957878</url>
  </required_header>
  <id_info>
    <org_study_id>PC10VAC02</org_study_id>
    <nct_id>NCT01957878</nct_id>
  </id_info>
  <brief_title>Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL</brief_title>
  <acronym>RHEIA-VAC</acronym>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genticel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genticel</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Finland: Finnish National Agency for Medicines</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix
      vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell
      carcinomas and 82% of adenocarcinomas of the cervix The strategy of therapeutic vaccination
      with ProCervix is to activate and enhance the patient's cellular immune response to HPV .
      The therapeutic vaccine will be used for women infected by HPV 16, HPV 18, or both. The
      vaccine targets these HPV infected women with normal or mild cervical cellular dyskaryosis
      as detectable infections with oncogenic potential.

      This will be a double-blind, randomised, placebo-controlled, parallel group study assessing
      the efficacy of ProCervix or placebo (concomitantly administered with imiquimod cream).

      ProCervix will be delivered with a topical agent, imiquimod, applied to the injection sites
      as a vaccine adjuvant.

      The population proposed for this study represents an otherwise healthy female population who
      are infected with HPV 16 and/or HPV 18. The safety and tolerability of this therapeutic
      vaccine has been shown in the ongoing Phase I study, and the proposed population may in
      theory derive benefit from this vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clearance  of HPV 16 and HPV 18 infection at Month 12 using a type specific, sensitive and quantitative HPV PCR assay.</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance  of HPV 16 and HPV 18 infection.</measure>
    <time_frame>Month 6, 15, 18, 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Genital Infection Viral</condition>
  <condition>HUMAN PAPILLOMA VIRUS</condition>
  <arm_group>
    <arm_group_label>HPV therapeutic vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo matching ProCervix</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProCervix</intervention_name>
    <description>ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
    <arm_group_label>HPV therapeutic vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod</description>
    <arm_group_label>Placebo matching ProCervix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject will be eligible for inclusion in this study if the following criteria
             apply:

               1. Subject is female between the ages of 25 and 50 years (inclusive).

               2. Subject is pre-menopausal .

               3. Subject must have cervical HPV 16 and/or 18 infection confirmed by RT-PCR

               4. Subject has a cervical cytological evaluation with a normal, ASCUS or LSIL
                  result at baseline.

               5. Subject has employed highly effective contraception the month prior to the first
                  vaccination and will agree to employ highly effective contraception for at least
                  12 months after the first vaccination. .

               6. Subject is in general good health based on medical history and physical
                  examination.

               7. Subject is able to communicate effectively with study personnel and is
                  considered reliable, willing, and cooperative in terms of compliance with the
                  protocol requirements.

               8. Subject voluntarily gives written informed consent to participate in the study.

        Exclusion Criteria:

          1. Subject has a current acute or chronic disease, other than infection with HPV, which
             would be expected to interfere with the planned evaluations of response

          2. Subject has vaginal atrophy with or without topical hormonal therapies or systemic
             selective estrogen receptor modulators (SERMs).

          3. Subject has prior exposure to HPV prophylactic vaccine or subject has participated in
             the past in another vaccination clinical trial related to infection with HPV

          4. Current high grade lesions or history of untreated high grade cervical lesion (either
             CIN2 or CIN3).

          5. Subject has current or a history of cancer of the cervix.

          6. Subject has clinically significant (CS) gynaecological abnormalities that could
             interfere with study evaluation, in the judgment of the Investigator (e.g. prolapse,
             myoma, fibroid, hysterectomy).

          7. Subject has a laboratory abnormality Grade ≥ 2, as defined using the Toxicity Grading
             Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine
             Clinical Trials,

          8. Subject has received any live viral vaccine within 3 months or any other non live
             vaccine within 2 weeks of first study product administration.

          9. Subject has primary or secondary systemic immunosuppression

         10. Subject has a history of severe allergy (requiring hospital care) or history of
             severe asthma

         11. Subject has a history of malignant cancer, except the following adequately treated
             cancers: basal cell carcinoma, or dermatological squamous cell carcinoma.

         12. Subject was administered with another investigational drug or vaccine within 30 days
             prior to the screening visit or is participating in any other study.

         13. Subject has a known hypersensitivity to imiquimod.

         14. Subject has a history of severe reaction to any drug or vaccination.

         15. Subject has a medical condition with clinical and/or biological consequences judged
             by the Investigator incompatible with vaccination(s).

         16. Subject has positive results for human immunodeficiency virus (HIV), hepatitis B
             virus (HBV) surface antigen (HBsAg), or hepatitis C virus (HCV).

         17. Subject has a symptomatic vaginal or genital infection

         18. Subject has a history of or currently active genital herpes disease.

         19. Subject is pregnant or is breastfeeding.

         20. Subject has a positive serum human chorionic gonadotrophin (HCG) result at enrolment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen Hospital</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams Brabant</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Donders, MD</last_name>
      <email>gilbert.donders@femicare.net</email>
    </contact>
    <investigator>
      <last_name>Gilbert Donders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for the Evaluation of Vaccination Vaccine &amp; Infectious Disease Institute (VAXINFECTIO) Faculty of Medicine University of Antwerp Belgium</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Van Damme, MD, PhD</last_name>
      <email>pierre.vandamme@uantwerpen.be</email>
    </contact>
    <investigator>
      <last_name>Pierre Van Damme, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi Site Notre-Dame</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Guy Sartenaer, MD</last_name>
      <email>jean.sartenaer@skynet.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Guy Sartenaer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willy Poppe, MD</last_name>
      <email>willy.poppe@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Willy Poppe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pekka Nieminen, MD</last_name>
      <email>pekka.nieminen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Pekka Nieminen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjo Tuppurainen, MD</last_name>
      <email>marjo.tuppurainen@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Marjo Tuppurainen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Mäenpää, MD</last_name>
      <email>johanna.maenpaa@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Johanna Mäenpää, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Gondry, MD</last_name>
      <email>gondry.jean@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Gondry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Jacques</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier Riethmuller, MD</last_name>
      <email>didier.riethmuller@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Riethmuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GORH, CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Gaelle Rabishong Kaermmerlen, MD</last_name>
      <email>agkaemmerlen@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Gaelle Rabishong Kaermmerlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge Douvier, MD</last_name>
      <email>serge.douvier@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Serge Douvier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katty Ardaens, MD</last_name>
      <email>katty.ardaens@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Katty Ardeans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hopital Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Letouzey, MD</last_name>
      <email>vincent.letouzey@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Letouzey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur (CIC BT505)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile Launay, MD</last_name>
      <email>odile.launay@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Odile Launay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aude Lunel-Potencier, MD</last_name>
      <email>aude.lunel@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Aude Lunel-Potencier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims Institut Alix de Champagne</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Paul Bory, MD</last_name>
      <email>jpbory@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Paul Bory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Jacques Baldauf, MD</last_name>
      <email>jean-jacques.baldauf@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Baldauf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin Hospital</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Günter Cichon, MD</last_name>
      <email>guenter.cichon@charite.de</email>
    </contact>
    <investigator>
      <last_name>Günter Cichon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Hospital</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grit Mehlhorn, MD</last_name>
      <email>grit.mehlhorn@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Grit Mehlhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Essen GmbH - Clinic/Outpatient Facility</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Piczlewicz, MD</last_name>
      <email>f.piczlewicz@contilia.de</email>
    </contact>
    <investigator>
      <last_name>Frank Piczlewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich Schiller Universität Jena Hospital</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelia Scheungraber, MD</last_name>
      <email>cornelia.scheungraber@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Cornelia Scheungraber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität- Hospital</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Dannecker, MD</last_name>
      <email>christian.dannecker@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Dannecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wolfsburg Hospital</name>
      <address>
        <city>Wolfsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Ulrich Petry, MD</last_name>
      <email>k.u.petry@klinikum.wolfsburg.de</email>
    </contact>
    <investigator>
      <last_name>Karl Ulrich Petry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center Gynaecological Oncology Amsterdam AMC, NKI-AVL, VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gemma Kenter, MD</last_name>
      <email>g.kenter@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Gemma Kenter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jules Schagen Van Leeuwen, MD</last_name>
      <email>j.schagen@antonius.net</email>
    </contact>
    <investigator>
      <last_name>Jules Schagen Van Leeuwen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Dept of Obstetrics and Gynecology C/ Villarroel Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic, Instituto de Investigaciones Biomédi</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurell Torne-Blade, MD</last_name>
      <email>atorne@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Aurell Torne-Blade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Mancebo, MD</last_name>
      <email>gmancebo@parcdesaiutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Gemma Mancebo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Centeno Mediavilla, MD</last_name>
      <email>criscent@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Cristina Centeno Mediavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia L'Hopitalet de Llobregat</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Castellsagué, MD</last_name>
      <email>xcastellsague@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>X Castellsagué, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ginecologica Ceoga, Clinic/Outpatient Facility</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Vazquez Fernandez</last_name>
      <email>fvazquezf@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Francisco Vazquez Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Serrano Velasco, MD</last_name>
      <email>mserranovelasco@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Serrano Velasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Antonio Vidart Aragon, MD</last_name>
      <email>jvidarta@sego.es</email>
    </contact>
    <investigator>
      <last_name>Jose Antonio Vidart Aragon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario &quot;12 de Octubre&quot;</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Jimenez López, MD</last_name>
      <email>jjimenezl@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Jesus Jimenez López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya - Hospital Materno Infantil</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia del Carmen Villegas Muñoz, MD</last_name>
      <email>evillegasm@sego.es</email>
    </contact>
    <investigator>
      <last_name>Emilia del Carmen Villegas Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sagrado Corazón de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Antonio Vargas Lazcano, MD</last_name>
      <email>joseantonio@vargaslazcano.es</email>
    </contact>
    <investigator>
      <last_name>José Antonio Vargas Lazcano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dumfries and Galloway Royal Infirmary Hospital</name>
      <address>
        <city>Dumfries</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Currie, MD</last_name>
      <email>heather.currie@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Heather Currie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool - GUM - Liverpool Centre for Sexual Health</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Lawton, MD</last_name>
      <email>mark@marklawton.com</email>
    </contact>
    <investigator>
      <last_name>Mark Lawton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deidre Lyons, MD</last_name>
      <email>Deirdre.Lyons@imperial.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Deidre Lyons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic O&amp;G University of Manchester Research - St Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Kitchener, MD</last_name>
      <email>henry.c.kitchener@manchester.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Henry Kitchener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Centre for Immunology and Infection Hull York Medical School University of York</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Lacey, MD, PhD</last_name>
      <email>charles.lacey@hyms.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Charles Lacey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
